Oryzon Genomics SA - Asset Resilience Ratio

Latest as of December 2025: 0.01%

Oryzon Genomics SA (ORY) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Oryzon Genomics SA to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€14.58K

≈ $17.05K USD Cash + Short-term Investments

Total Assets

€144.52 Million

≈ $168.96 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Oryzon Genomics SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Oryzon Genomics SA.

Liquid Assets Composition Over Time

This chart breaks down Oryzon Genomics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ORY long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€14.58K	0.01%
Total Liquid Assets	€14.58K	0.01%

Asset Resilience Insights

Limited Liquidity: Oryzon Genomics SA maintains only 0.01% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Oryzon Genomics SA Industry Peers by Asset Resilience Ratio

Compare Oryzon Genomics SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Oryzon Genomics SA (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Oryzon Genomics SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.01%	€14.58K ≈ $17.05K	€144.52 Million ≈ $168.96 Million	--
2020-12-31	0.00%	€0.00 ≈ $0.00	€94.11 Million ≈ $110.02 Million	--
2019-12-31	0.18%	€141.56K ≈ $165.49K	€80.09 Million ≈ $93.64 Million	-0.03pp
2018-12-31	0.21%	€141.56K ≈ $165.49K	€67.45 Million ≈ $78.86 Million	-0.14pp
2017-12-31	0.35%	€213.18K ≈ $249.23K	€61.04 Million ≈ $71.37 Million	-10.19pp
2016-12-31	10.54%	€5.24 Million ≈ $6.13 Million	€49.74 Million ≈ $58.16 Million	+4.99pp
2015-12-31	5.55%	€2.26 Million ≈ $2.64 Million	€40.73 Million ≈ $47.62 Million	-16.10pp
2014-12-31	21.65%	€5.64 Million ≈ $6.60 Million	€26.06 Million ≈ $30.46 Million	+21.16pp
2013-12-31	0.49%	€142.00K ≈ $166.01K	€28.76 Million ≈ $33.63 Million	-1.26pp
2012-12-31	1.76%	€506.00K ≈ $591.57K	€28.78 Million ≈ $33.65 Million	-6.15pp
2011-12-31	7.91%	€2.31 Million ≈ $2.70 Million	€29.21 Million ≈ $34.15 Million	--

pp = percentage points

About Oryzon Genomics SA

MC:ORY Spain Biotechnology

Market Cap

$253.38 Million

€216.73 Million EUR

Market Cap Rank

#16391 Global

#107 in Spain

Share Price

€2.80

Change (1 day)

+0.72%

52-Week Range

€2.68 - €3.82

All Time High

€5.14